Get the Stockscreener App
2.6207
1.95%
0.0507
Annovis Bio Inc stock is traded at $2.6207, with a volume of 10,482.
It is up +1.95% in the last 24 hours and down -0.76% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
See More
Previous Close:
$2.57
Open:
$2.56
24h Volume:
10,482
Relative Volume:
0.02
Market Cap:
$51.07M
Revenue:
-
Net Income/Loss:
$-40.94M
P/E Ratio:
-0.6825
EPS:
-3.84
Net Cash Flow:
$-22.97M
1W Performance:
-4.38%
1M Performance:
-0.76%
6M Performance:
-48.73%
1Y Performance:
-75.40%
1-Day Range:
$2.5303
$2.70
1-Week Range:
$2.52
$2.8899
52-Week Range:
$1.11
$11.69
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
2.6207 | 52.22M | 0 | -40.94M | -22.97M | -3.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.41 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.25 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.79 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.93 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.27 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
What drives Annovis Bio Inc. stock priceMassive portfolio appreciation - jammulinksnews.com
Is Annovis Bio Inc. a good long term investmentExplosive earnings growth - jammulinksnews.com
Annovis Bio Inc. Stock Analysis and ForecastSuperior investment outcomes - jammulinksnews.com
What analysts say about Annovis Bio Inc. stockPowerful growth strategies - jammulinksnews.com
Annovis Bio stock rating cut to hold at D. Boral Capital - MSN
Annovis Bio to Present Key Findings at Alzheimer’s Association International Conference - MSN
What risks could impact Annovis Bio Inc. stock performanceCapital Growth Picks - Newser
Annovis Bio Inc. Advances Alzheimer’s Treatment with Buntanetap Study - TipRanks
Why Annovis Bio Inc. stock attracts strong analyst attentionCapital Preservation Investment Ideas - newser.com
What makes Annovis Bio Inc. stock price move sharplyFree Popular Stock Recommendations - Newser
How Annovis Bio Inc. stock performs during market volatilityCapital Growth Picks - newser.com
Annovis Bio's Volatility Trap: Why Risky Bets and Biotech Headwinds Spell Caution for Investors - AInvest
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress - MSN
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR.com
Annovis Bio’s Alzheimer’s Study: A Potential Game-Changer for Investors? - TipRanks
Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025 - citybuzz -
Annovis Bio Plunges 10.13% on Analyst Price Target Cut - AInvest
Annovis Bio (ANVS) Stock Jumps Over 16% in Market Trading | ANVS Stock News - GuruFocus
Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development - MSN
Annovis Bio Approves Board Elections and Auditor Appointment - TipRanks
We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully - Yahoo Finance
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window - FinancialContent
Annovis Bio Secures NYSE Approval to Regain Compliance with Listing Standards - MSN
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance - The Manila Times
10,923 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Two Sigma Investments LP - Defense World
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy - MSN
HC Wainwright Has Optimistic View of Annovis Bio Q2 Earnings - Defense World
Q1 Earnings Forecast for Annovis Bio Issued By HC Wainwright - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Annovis Bio (NYSE:ANVS) Price Target Cut to $12.00 by Analysts at HC Wainwright - Defense World
Annovis Bio (ANVS) Price Target Cut by 60% by HC Wainwright | AN - GuruFocus
Annovis Bio stock price target cut to $12 at H.C. Wainwright By Investing.com - Investing.com South Africa
Annovis Bio stock price target cut to $12 at H.C. Wainwright - Investing.com Nigeria
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.56%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):